CYBIN INC (CYBN)

CA23256X1006 - Common Stock

9.61  +0.29 (+3.11%)

After market: 9.95 +0.34 (+3.54%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CYBN. CYBN was compared to 193 industry peers in the Pharmaceuticals industry. While CYBN has a great health rating, there are worries on its profitability. CYBN does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYBN has reported negative net income.
In the past year CYBN has reported a negative cash flow from operations.
CYBN had negative earnings in each of the past 5 years.
CYBN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CYBN has a Return On Assets of -47.14%. This is in the lower half of the industry: CYBN underperforms 61.78% of its industry peers.
Looking at the Return On Equity, with a value of -48.50%, CYBN is in line with its industry, outperforming 57.07% of the companies in the same industry.
Industry RankSector Rank
ROA -47.14%
ROE -48.5%
ROIC N/A
ROA(3y)-54.26%
ROA(5y)N/A
ROE(3y)-60.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYBN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for CYBN has been increased compared to 1 year ago.
CYBN has a worse debt/assets ratio than last year.

2.2 Solvency

CYBN has an Altman-Z score of 20.41. This indicates that CYBN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CYBN (20.41) is better than 91.10% of its industry peers.
There is no outstanding debt for CYBN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.41
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CYBN has a Current Ratio of 24.24. This indicates that CYBN is financially healthy and has no problem in meeting its short term obligations.
CYBN's Current ratio of 24.24 is amongst the best of the industry. CYBN outperforms 94.24% of its industry peers.
A Quick Ratio of 24.24 indicates that CYBN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 24.24, CYBN belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.24
Quick Ratio 24.24

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CYBN have decreased strongly by -1688.00% in the last year.
The Revenue for CYBN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1688%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5620%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CYBN will show a very strong growth in Earnings Per Share. The EPS will grow by 84.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2064.07%
EPS Next 2Y-405.14%
EPS Next 3Y-111.08%
EPS Next 5Y84.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYBN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYBN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CYBN's earnings are expected to decrease with -111.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-405.14%
EPS Next 3Y-111.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYBN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYBIN INC

NYSEARCA:CYBN (12/20/2024, 8:04:38 PM)

After market: 9.95 +0.34 (+3.54%)

9.61

+0.29 (+3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners38.51%
Inst Owner Change-76.95%
Ins Owners6.92%
Ins Owner ChangeN/A
Market Cap192.10M
Analysts82.86
Price TargetN/A
Short Float %2.52%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-74.4%
Min EPS beat(2)-192.79%
Max EPS beat(2)43.98%
EPS beat(4)2
Avg EPS beat(4)-53.88%
Min EPS beat(4)-192.79%
Max EPS beat(4)53.86%
EPS beat(8)4
Avg EPS beat(8)-32.09%
EPS beat(12)6
Avg EPS beat(12)-19.75%
EPS beat(16)6
Avg EPS beat(16)-38.43%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5047.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-3700%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-7.1
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.47
OCFYN/A
SpS0
BVpS8.87
TBVpS5.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.14%
ROE -48.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.26%
ROA(5y)N/A
ROE(3y)-60.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 170.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.24
Quick Ratio 24.24
Altman-Z 20.41
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1688%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5620%
EPS Next Y-2064.07%
EPS Next 2Y-405.14%
EPS Next 3Y-111.08%
EPS Next 5Y84.05%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-149.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.85%
EBIT Next 3Y-17.52%
EBIT Next 5Y-12.92%
FCF growth 1Y-137.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.59%
OCF growth 3YN/A
OCF growth 5YN/A